Who Paid My Doc
John Flack
Hypertension Specialist Springfield, IL Medical Doctor
NPI 1164450987 CMS profile 7566
751 N Rutledge St, Suite 1100, Springfield, IL 62702
General payments
$157,771
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$193,281
Through program year 2025, John Flack of Springfield, IL is reported in the CMS Open Payments database as having received $157,771 across 106 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $193,281 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $25,636 | 33 | |
| 2024 | General | $76,171 | 36 | |
| 2023 | General | $16,284 | 9 | |
| 2022 | General | $27,686 | 18 | |
| 2021 | General | $2,250 | 2 | |
| 2019 | General | $9,744 | 8 |
Beside peers
- John Flack
- Illinois median
- Middle half of Illinois
- National median
In program year 2025, general payments to John Flack were reported at $25,636. Among 38,505 Illinois profiles paid that year, the median was $163 and the middle half received between $50 and $568.
Show as a table
| Year | John Flack | Illinois median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $9,744 | $151 | $49–$575 | $163 |
| 2020 | $0 | $105 | $32–$363 | $114 |
| 2021 | $2,250 | $124 | $36–$426 | $132 |
| 2022 | $27,686 | $138 | $41–$499 | $149 |
| 2023 | $16,284 | $148 | $45–$517 | $160 |
| 2024 | $76,171 | $154 | $47–$535 | $164 |
| 2025 | $25,636 | $163 | $50–$568 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 21 drugsPart D claims
1,207
Drug cost
$95,834
Branded share of claims
15%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Entresto Sacubitril/Valsartan | Brand | 68 | $53,642 | |
| Farxiga Dapagliflozin Propanediol | Brand | 18 | $30,992 | |
| Olmesartan Medoxomil | Generic | 223 | $2,403 | |
| Chlorthalidone | Generic | 140 | $1,390 | |
| Verapamil Er Verapamil Hcl | Brand | 37 | $1,372 | |
| Isosorbide Mononitrate Er Isosorbide Mononitrate | Brand | 47 | $1,098 | |
| Indapamide | Generic | 108 | $934 | |
| Amlodipine Besylate | Generic | 127 | $656 | |
| Allopurinol | Generic | 126 | $571 | |
| Metoprolol Succinate | Generic | 78 | $527 |
The 10 drugs with the highest cost, of 21 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 5 billing codesPaid by Medicare
$4,563
Medicare patients
44
Services billed
55
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 41% | |
| Diabetes | 39% | |
| Chronic kidney disease | 34% | |
| Arthritis | 32% | |
| Atrial fibrillation | 27% | |
| Depression | 25% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
106 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hypertension Specialist in Illinois
Related records
Hypertension Specialist in Illinois
Practitioners in the same specialty and state, ranked by reported value.
All Hypertension Specialist
Everyone recorded under this specialty, nationwide.
Doctors in Illinois
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.